AIT Therapeutics (OTCMKTS:AITB) and Endologix (NASDAQ:ELGX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.
This is a summary of current recommendations and price targets for AIT Therapeutics and Endologix, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
AIT Therapeutics currently has a consensus target price of $16.00, suggesting a potential upside of 226.53%. Endologix has a consensus target price of $3.86, suggesting a potential upside of 155.44%. Given AIT Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe AIT Therapeutics is more favorable than Endologix.
Institutional and Insider Ownership
94.0% of Endologix shares are held by institutional investors. 4.1% of Endologix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares AIT Therapeutics and Endologix’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|AIT Therapeutics||N/A||N/A||-$18.04 million||($3.01)||-1.63|
|Endologix||$181.16 million||0.71||-$66.40 million||($0.48)||-3.15|
AIT Therapeutics has higher earnings, but lower revenue than Endologix. Endologix is trading at a lower price-to-earnings ratio than AIT Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
AIT Therapeutics has a beta of 2.84, indicating that its share price is 184% more volatile than the S&P 500. Comparatively, Endologix has a beta of 0.01, indicating that its share price is 99% less volatile than the S&P 500.
This table compares AIT Therapeutics and Endologix’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
AIT Therapeutics beats Endologix on 7 of the 12 factors compared between the two stocks.
AIT Therapeutics Company Profile
AIT Therapeutics, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria. The company was founded in 2011 and is based in Harrison, New York.
Endologix Company Profile
Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system. The company also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, it offers proximal aortic extensions and limb extensions which allows physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. The company offers its EVAR products under Ovation, Powerlink System, IntuiTrak, AFX, VELA Proximal Endograft brand names; and EVAS products under the Nellix EVAS system brand name. It sells its products through direct sales force, network of agents, and independent distributors or agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.
Receive News & Ratings for AIT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.